{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:42:53Z","timestamp":1793162573261,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cgh.2022.12.029","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T02:23:12Z","timestamp":1672971792000},"page":"2616-2628.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study"],"prefix":"10.1016","volume":"21","author":[{"given":"William J.","family":"Sandborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Leszczyszyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Romatowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Hassan-Zahraee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmalatha S.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Banfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Salganik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.12.029_bib1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.029_bib2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2022.12.029_bib3","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.029_bib4","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2022.12.029_bib5","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.cgh.2022.12.029_bib6","first-page":"10","article-title":"Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment","author":"Dudek","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cgh.2022.12.029_bib10","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.cgh.2022.12.029_bib11","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of (( S)-2,2-difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cgh.2022.12.029_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A\u00a0phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2022.12.029_bib13","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2022.12.029_bib14","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.cgh.2022.12.029_bib15","doi-asserted-by":"crossref","first-page":"S030","DOI":"10.1093\/ecco-jcc\/jjab075.032","article-title":"Oral ritlecitinib and brepocitinib in patients with moderate to severe active ulcerative colitis: data from the VIBRATO umbrella study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2022.12.029_bib16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3389\/fimmu.2019.00961","article-title":"Human gut-associated natural killer cells in health and disease","volume":"10","author":"Poggi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.cgh.2022.12.029_bib17","article-title":"New insights on CD8","volume":"12","author":"Casalegno Gardu\u00f1o","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.cgh.2022.12.029_bib18","doi-asserted-by":"crossref","first-page":"a002287","DOI":"10.1101\/cshperspect.a002287","article-title":"T-cell signaling regulated by the Tec family kinase, Itk","volume":"2","author":"Andreotti","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.cgh.2022.12.029_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41419-021-03702-y","article-title":"Bruton\u2019s tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response","volume":"12","author":"Guan","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cgh.2022.12.029_bib20","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1053\/j.gastro.2021.06.072","article-title":"Targeting of the Tec kinase ITK drives resolution of T cell-mediated colitis and emerges as potential therapeutic option in ulcerative colitis","volume":"161","author":"Lechner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.029_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102842","article-title":"Targeting ITK signaling for T cell-mediated diseases","volume":"24","author":"Weeks","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.cgh.2022.12.029_bib22","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ibd\/izab135","article-title":"Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise","volume":"27","author":"Danese","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2022.12.029_bib23","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn\u2019s disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2022.12.029_bib24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.immuni.2019.06.008","article-title":"Temporally distinct functions of the cytokines IL-12 and IL-23 drive chronic colon inflammation in response to intestinal barrier impairment","volume":"51","author":"Eftychi","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cgh.2022.12.029_bib25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2018.01.045","article-title":"Anti-IL-23 receptor monoclonal antibody prevents CD4","volume":"824","author":"Imamura","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cgh.2022.12.029_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0016-5085(94)90585-1","article-title":"Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease\u2014Canadian Crohn\u2019s Relapse Prevention Trial Study Group","volume":"106","author":"Irvine","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.12.029_bib27","series-title":"Analyzing longitudinal clinical trial data: a practical guide","author":"Mallinckrodt","year":"2017"},{"key":"10.1016\/j.cgh.2022.12.029_bib28","series-title":"Applied longitudinal analysis","author":"Fitzmaurice","year":"2011"},{"key":"10.1016\/j.cgh.2022.12.029_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/01621459.1983.10477938","article-title":"Binomial confidence intervals","volume":"78","author":"Blyth","year":"1983","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.cgh.2022.12.029_bib30","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2307\/3314658","article-title":"Refining binomial confidence intervals","volume":"14","author":"Casella","year":"1986","journal-title":"Can J Stat"},{"key":"10.1016\/j.cgh.2022.12.029_bib31","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"10.1016\/j.cgh.2022.12.029_bib32","series-title":"Efficacy and safety of ritlecitinib (PF-06651600) in patients with alopecia areata and \u226550% scalp hair loss: results from the International ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled study","author":"King","year":"2021"},{"key":"10.1016\/j.cgh.2022.12.029_bib33","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.cgh.2022.12.029_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.537","article-title":"Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in\u00a0vitro cytokine receptor inhibition","volume":"7","author":"Dowty","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.cgh.2022.12.029_bib35","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.cgh.2022.12.029_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrrheum.2017.51","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.cgh.2022.12.029_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cgh.2022.12.029_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13148","article-title":"The effect of Bruton\u2019s tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)","author":"Chen","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cgh.2022.12.029_bib39","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2022.12.029_bib40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A\u00a0review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523000071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523000071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:44:34Z","timestamp":1761543874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523000071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1542356523000071"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.12.029","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}